Before Comedy Central, TikTok videos, and other social media inventions, Monty Python entertained us (admittedly, an acquired taste). Many of us remember the classic scene from the 1975 movie Monty ...

If acquiring a product from another company, it is important to consider, during due diligence and post-acquisition stages, any past OPDP communications about the particular product’s promotional ...

Amid the recent widespread cuts to the Department of Health and Human Services, one impacted entity stands out: the Office of Prescription Drug Promotion (OPDP). Housed under the Food and Drug ...

Looking back to 2020, the acting director of the US Food and Drug Administration’s Office of Prescription Drug Promotion (FDA’s OPDP) highlighted the office’s major initiatives and successes. Speaking ...

Bausch Health has drawn scrutiny for a promotional video and web page that, regulators said, misbranded its prescription psoriasis cream Duobrii. Bausch was targeted because the video and web page ...

The US Food and Drug Administration’s (FDA) Office of Prescription Drug Promotion (OPDP) broke its year-long silent streak when it sent an untitled letter to Xeris Pharmaceuticals concerning the ...

Sometimes it seems that the FDA has a scattershot approach to policing pharma marketing, with warning letters few and far between--and some of them lobbed from left field. But there's one ...

It’s no Kardashian kerfuffle, but the FDA's ad police have sent their first letter of the year. The untitled letter sent to Collegium Pharmaceuticals tackles a hot-topic category, opioids, over a ...

FDA officials have been busy rolling out advisories for pharma marketers, and there’s no let-up in sight, writes Jill Wechsler. FDA officials have been busy rolling out advisories for pharma marketers ...

“31% of patients had normal cortisol levels after taking Recorlev for 6 months without changing their dose.” “67% of patients who moved on to the second part of the study had normal cortisol levels by ...

In 2015, the US pharmaceutical industry saw a significant decrease in the number of violation letters issued by FDA’s Office of Prescription Drug Promotion (OPDP)–A decrease that marks an all-time low ...